Optimising Treatment of HF

Published: 21 April 2021

  • Views:

    Views Icon 8931

  • Likes:

    Heart Icon 7

Overview

Full programme

  • Views:

    Views Icon 8931

  • Likes:

    Heart Icon 7
Download Slides

Overview

Following recent changes to guidelines in light of the publication of Phase III data with SGLT2 inhibitors in patients with HFrEF, with and without type 2 diabetes, this programme brings together a leading faculty to best inform of the latest clinical evidence and real-world application for optimising treatment strategies in heart failure.

 

Prof Martin Cowie (Imperial College London, UK), moderates the proceedings, that comprises a number of insightful presentations and a panel discussion, with contributions from Prof Giuseppe Rosano (St George's Hospitals NHS Trust, London, UK), Dr Javed Butler (University of Mississippi, US), and Dr Shelley Zieroth (University of Manitoba, Canada).

Intended for healthcare professionals only. This IME programme is supported by an unrestricted educational grant from AstraZeneca, who has had no involvement in its organisation. Views and opinions expressed in the programme belong to the authors (faculty and delegates) and not necessarily to that of AstraZeneca.

Learning objectives

  • Recall recent changes to guidelines following the publication of Phase III data with SGLT2 inhibitors in patients with HFrEF, with and without type 2 diabetes
  • Describe the type and extent of clinical benefit observed when SGLT2 inhibitors are added to standard HF therapy in patients with HFrEF
  • Assimilate prevailing hypotheses and insights from key thought leaders on optimal therapeutic sequencing of the ‘five pillars’ of HF therapy
  • Apply newly gained knowledge on therapeutic sequencing to surrogate patient cases

Audience

  • Heart Failure Specialists
  • General Cardiologists
  • Nurses
  • Allied Health Professionals

Series overview

Part 1

PART 1 – Introduction – Optimising Treatment of HF

Prof Martin Cowie introduces the topic, and reviews the learning objectives of the programme.

1 session

  • PART 1 – Introduction – Optimising Treatment of HF

    Watch now

Part 2

PART 2 – A Review of Recent SGLT2 Inhibitor Data

Prof Giuseppe Rosano reviews recent SGLT2 trial data, including DAPA – HF, and Emperor Reduced.

1 session

  • PART 2 – A Review of Recent SGLT2 Inhibitor Data

    Watch now

Part 3

PART 3 – New HFrEF: When and How Should We Initiate an SGLT2 Inhibitor?

Dr Javed Butler presents a case, and considers available treatment strategies, and the optimal approach for HFrEF medications.

1 session

  • PART 3 – New HFrEF: When and How Should We Initiate an SGLT2 Inhibitor?

    Watch now

Part 4

PART 4 – Existing HF-REF: Augmenting the SOC

Dr Shelley Zieroth reviews how guideline-directed medical therapy for HFrEF has evolved, and notes that further changes are coming to practice.

1 session

  • PART 4 – Existing HF-REF: Augmenting the SOC

    Watch now

Part 5

PART 5 – How Will SGLT2 Inhibition Provide the Greatest Impact on HF-REF?

Prof Cowie moderates a discussion with the faculty.

1 session

  • PART 5 – How Will SGLT2 Inhibition Provide the Greatest Impact on HF-REF?

    Watch now

Faculty biographies